Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
BridgeBio (NASDAQ: BBIO) reported $194.5M total revenue for Q1 2026, including $180.6M of U.S. Attruby net product revenue, and $940.2M in cash, cash equivalents and marketable securities as of March 31, 2026. The Board authorized a $500M share repurchase program.
Pipeline updates: NDA submitted for BBP-418 (LGMD2I/R9); encaleret NDA planned 1H 2026; infigratinib NDA planned Q3 2026. Attruby approvals expanded (Brazil) and new survival and real-world data presented at major meetings.
BridgeBio (Nasdaq: BBIO) announced management will participate in investor fireside chats at three healthcare conferences in May–June 2026: BofA Health Care Conference (May 12, 2:20 pm PDT), Jefferies Global Healthcare Conference (June 4, 11:05 am EDT), and Goldman Sachs Global Healthcare Conference (June 9, 8:00 am EDT).
Live webcasts will be available via the company’s Events and Presentations investor page and replays will remain online for 90 days after each event.
BridgeBio (Nasdaq: BBIO) announced ANVISA approval of BEYONTTRA (acoramidis) to treat wild-type or variant transthyretin amyloidosis cardiomyopathy (ATTR-CM) in adults in Brazil. Approval follows the Phase 3 ATTRibute-CM trial (632 patients) showing a 42% reduction in composite all-cause mortality and recurrent CV hospitalization and a 50% reduction in cumulative CV hospitalizations at Month 30. BEYONTTRA is described as a near-complete (≥90%) TTR stabilizer and already carries approvals in the U.S., EU, UK, Switzerland, and Japan. Commercialization in Brazil is planned with Biopas beginning in H2 2026.
BridgeBio (NASDAQ: BBIO) will present primary Phase 3 CALIBRATE results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1) at the 2026 European Congress of Endocrinology (ECE) in Prague.
Presentations include two oral talks (May 12), one poster (P72) and one ePoster (EP260); presenters include Filomena Cetani and Arun Mathew.
BridgeBio (NASDAQ: BBIO) announced presentations of new Phase 3 ATTRibute-CM data for acoramidis at ESC-Heart Failure 2026 in Barcelona on May 9–12, 2026.
Highlights include a late-breaking oral presentation by Bayer on outpatient worsening heart failure, data on NT-proBNP at Month 30, and KCCQ-OS quality-of-life results.
BridgeBio (Nasdaq: BBIO) will report first quarter 2026 financial results and provide commercial and program updates after market close on Thursday, May 7, 2026.
A conference call and live webcast will begin at 4:30 pm ET. A replay will be available on the company website for 30 days.
BridgeBio (Nasdaq: BBIO) launched a national health-education campaign, Don’t Pass On Your Heart Health, to raise awareness of ATTR-CM and encourage earlier diagnosis and care among adults over 55.
The effort features Morgan Freeman and Howard “H” White, highlights findings from the Phase 3 ATTRibute-CM study showing treatment benefits with Attruby, and provides resources at Attruby.com.
BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved April 18, 2026, for 33 new employees totaling 67,247 restricted stock units.
Vesting: 25% vests on May 16, 2027, then one‑twelfth of the remainder quarterly thereafter, subject to continued employment. Awards were granted under the company’s plan adopted November 2019 and amended February 10, 2023 and December 13, 2023.
BridgeBio (Nasdaq: BBIO) presented long-term data showing acoramidis provides sustained benefit through Month 54 in ATTR-CM. Continuous treatment reduced all-cause mortality by 44.7% and cardiovascular mortality by 49.3% (both p<0.0001) versus placebo-to-acoramidis.
Acoramidis mitigated NT-proBNP rise, stabilized KCCQ-OS heart-failure scores, was well tolerated long term, and is approved in the U.S., EU, Japan, Switzerland and the UK.
BridgeBio (Nasdaq: BBIO) submitted a New Drug Application to the FDA for oral BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) on March 30, 2026.
The NDA includes interim Phase 3 FORTIFY data showing statistically significant, clinically meaningful improvements in ambulation and pulmonary function and a favorable safety profile. BridgeBio anticipates U.S. approval and a launch in late 2026/early 2027, is seeking expedited paths in Europe, and notes prior Orphan Drug, Fast Track, and Rare Pediatric designations.